Avian Flu (H5N1) Drug Candidate Available For License

Roanoke, VA (PRWEB) June 4, 2007

Tallinn Group LLC, announced today the availability for immediate license of a promising broad spectrum influenza drug candidate targeted at the Avian (H5N1) flu market.

Originally developed for the oncology market, recent testing performed at the U.S. National Institutes of Health (NIH) has shown that the compound, designated “C46132″, demonstrated a remarkable efficacy against a suite of influenza viruses including H5N1 (Avian flu). C46132 at very low concentrations readily inactivated cell-free as well as cell associated Avian flu (H5N1) virus in addition to other influenza strains. Testing has also shown the compound to be very easily tolerated in-vivo.

Ted Grochowski, Jr., Principal, Tallinn Group, said, “It is our desire to license C46132 to a pharmaceutical partner that will lead the deployment of this revolutionary drug candidate. Our market analysis indicates the production costs of the active compound to be relatively inexpensive. We believe our lower production cost over vaccines along with greater shelf stability will enhance its global distribution as well as its ability to be strategically stockpiled for pandemic applications. We anticipate fast-track regulatory approval and subsequent rapid market entry compared to vaccines in development. Initial markets we’ve identified include the human influenza drug market with an emphasis on Avian flu. Other near term markets include the poultry industry and the manufacturers of sanitation products. We invite licensing inquiries from interested parties.”

The technology is protected by issued patents, patents pending and filed patent applications.

Tallinn Group LLC on the web at: www.tallinngroup.com.

For More Information Contact:

Ted Grochowski, Jr.

Tallinn Group LLC

US: 001.540.907.4860

UK: 44 020 8144 5151

###

Related Influenza Press Releases

Flu Symptoms Blog